Coadministration of Seasonal Flu Vaccine and Prevnar 20 Shows Promising Results

Pharmacy Times, November 2021, Volume 87, Issue 11

Findings from the phase 3 B7471004 study (NCT04526574) evaluating the immunogenicity and safety of pneumococcal 20-valent conjugate vaccine (Prevnar 20) coadministered with the seasonal influenza vaccine in adults 65 years and older showed positive top-line results, according to a statement from Pfizer.

A total of 1796 participants were enrolled and randomized in the study, with 1727 completing the study across 66 investigator sites in the United States. The responses provoked by Prevnar 20 for all 20 serotypes and by the seasonal influenza vaccine when given together were noninferior to those elicited by the vaccines when administered 1 month apart. Further, the safety profile of Prevnar 20 was similar when the vaccines were coadministered compared with when each was administered separately, 1 month apart, according to the study.

The investigators noted the importance of maintaining vaccination rates for conditions that can lead to respiratory issues, especially with COVID-19 cases still raising concern throughout the United States.

“Both Prevnar 20 and the influenza vaccine are important for helping protect adults against pneumococcal pneumonia and the flu, respectively. However, vaccination rates decline when someone needs to make multiple appointments to receive these vaccines,” Luis Jodar, PhD, senior vice president and chief medical officer at Pfizer Vaccines, said in a statement.

“The results of this trial support current CDC clinical guidance allowing coadministration during a single doctor or pharmacy appointment, so that more adults are able to help protect themselves against both of these respiratory diseases,” he said.

Reference

Positive top-line results of Pfizer’s phase 3 study exploring coadministration of Prevnar 20 with seasonal flu vaccine in older adults released. Pfizer. September 29, 2021. Accessed September 29, 2021. https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring